Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bittoo Kanwar

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Plos One|February 6, 2014
Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 productionMargaret M Lowe, Jeff E Mold, Bittoo Kanwar, et al.
Hepatology (Baltimore, Md.)|December 21, 2016
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infectionWilliam F Balistreri, Karen F Murray, Philip Rosenthal, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
Gastroenterology|September 2, 2021
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative ColitisWilliam J Sandborn, Larry C Mattheakis, Nishit B Modi, et al.
Science Translational Medicine|May 21, 2010
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV diseaseDavid Favre, Jeff Mold, Peter W Hunt, et al.
Hepatology (Baltimore, Md.)|May 26, 2017
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infectionStefan Wirth, Philip Rosenthal, Regino P Gonzalez-Peralta, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 28, 2016
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trialEric G Meissner, Mary McLaughlin, Lindsay Matthews, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Plos One|February 6, 2014
Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 productionMargaret M Lowe, Jeff E Mold, Bittoo Kanwar, et al.
Hepatology (Baltimore, Md.)|December 21, 2016
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infectionWilliam F Balistreri, Karen F Murray, Philip Rosenthal, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failedStanislas Pol, Mark S Sulkowski, Tarek Hassanein, et al.
Gastroenterology|September 2, 2021
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative ColitisWilliam J Sandborn, Larry C Mattheakis, Nishit B Modi, et al.
Science Translational Medicine|May 21, 2010
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV diseaseDavid Favre, Jeff Mold, Peter W Hunt, et al.
Hepatology (Baltimore, Md.)|May 26, 2017
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infectionStefan Wirth, Philip Rosenthal, Regino P Gonzalez-Peralta, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 28, 2016
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trialEric G Meissner, Mary McLaughlin, Lindsay Matthews, et al.
Pageof 2